Referências Bibliográficas
PFITZER,
T., NIEDERHOFFER, N. & SZABO, B. (2004). Central effects of the
cannabinoid receptor agonist WIN55212-2 on respiratory and cardiovascular
regulation in anaesthetised rats.
Br J Pharmacol, 142, 943-52.
PIOMELLI, D. (2003). The molecular logic of endocannabinoid signalling.
Nat Rev
Neurosci, 4, 873-84.
PIOMELLI, D., BELTRAMO, M., GIUFFRIDA, A. & STELLA, N. (1998). Endogenous
cannabinoid signaling.
Neurobiol Dis, 5, 462-73.
PIOMELLI D. (2005) The endocannabinoid system: a drug discovery perspective.
Curr Opin Investig Drugs. Jul;6(7):672-9.
POMPERMAYER,
K., AMARAL, F.A., FAGUNDES, C.T., VIEIRA, A.T., CUNHA,
F.Q., TEIXEIRA, M.M. & SOUZA, D.G. (2007). Effects of the treatment with
glibenclamide, an ATP-sensitive potassium channel blocker, on intestinal
ischemia and reperfusion injury.
Eur J Pharmacol, 556, 215-22.
PORTELLA G, LAEZZA C, LACCETTI P, DE PETROCELLIS L, DI MARZO V,
BIFULCO M. (2003) Inhibitory effects of cannabinoid CB1 receptor stimulation
on tumor growth and metastatic spreading: actions on signals involved in
angiogenesis and metastasis.
FASEB J. 2003 Sep;17(12):1771-3.
PORTER, A.C., SAUER, J.M., KNIERMAN, M.D., BECKER, G.W., BERNA, M.J.,
BAO, J., NOMIKOS, G.G., CARTER, P., BYMASTER, F.P., LEESE, A.B. &
FELDER, C.C. (2002). Characterization of a novel endocannabinoid,
virodhamine, with antagonist activity at the CB1 receptor.
J Pharmacol Exp
Ther, 301, 1020-4.
RAYMAN, N., LAM, K.H., LAMAN, J.D., SIMONS, P.J., LOWENBERG, B.,
SONNEVELD, P. & DELWEL, R. (2004). Distinct expression profiles of the
peripheral cannabinoid receptor in lymphoid tissues depending on receptor
activation status.
J Immunol, 172, 2111-7.
RHEE, M.H., BAYEWITCH, M., AVIDOR-REISS, T., LEVY, R. & VOGEL, Z. (1998).
Cannabinoid receptor activation differentially regulates the various adenylyl
cyclase isozymes.
J Neurochem, 71, 1525-34.
RINALDI-CARMONA, M., BARTH, F., HEAULME, M., SHIRE, D., CALANDRA, B.,
CONGY, C., MARTINEZ, S., MARUANI, J., NELIAT, G., CAPUT, D. & ET AL.
(1994). SR141716A, a potent and selective antagonist of the brain cannabinoid
receptor.
FEBS Lett, 350, 240-4.
RINALDI-CARMONA, M., BARTH, F., MILLAN, J., DEROCQ, J.M., CASELLAS, P.,
CONGY, C., OUSTRIC, D., SARRAN, M., BOUABOULA, M., CALANDRA, B.,
PORTIER, M., SHIRE, D., BRELIERE, J.C. & LE FUR, G.L. (1998). SR 144528,
the first potent and selective antagonist of the CB2 cannabinoid receptor.
J
Pharmacol Exp Ther
, 284, 644-50.
138